Just found this abstract on the ASCO Meeting Library web page.
Not sure if this is the latest news or a previous recap. Perhaps those with better medical insight than I could elaborate ??
Results:Between 04 Mar 19 and 31 Jan 2020, 48 pts were enrolled and evaluated for safety and exposure. The median age was 66 yrs (range 48-84) and 73 % were male. The ECOG was 0 in 50 % and 1 in 50 % of pts, respectively. Pts received a median of 5 (7) and in total 311 (413) pembrolizumab (efti) administrations, respectively. Three pts (6.3 %) discontinued study treatment due to AEs. The most common ( > 10%) adverse events (AEs) being cough (31 %), asthenia (23 %), decreased appetite (19 %), fatigue (19 %), dyspnea (17 %), diarrhea (15 %) and constipation 13 %). From part A all pts (n = 17) were evaluated. Eight pts (47 %) had a partial response (iPR) and six (35 %) had stable disease according to iRECIST representing an ORR (DCR) of 47 % (82 %). irPRs were observed in all different PD-L1 groups ( < 1%; ≥ 1 % ≤49 %; ≥ 50 %). Ten (10; 59 %) pts are still on therapy (8+ months). In part C stage 1 15/18 pts are evaluable and six (40 %) had an iPR to date.Conclusions:Efti in combination with pembrolizumab is safe and shows encouraging antitumor activity in all comer PD-L1 1st line NSCLC and 2nd line HNSCC. Stage 2 has opened for both parts. Clinical trial information: NCT03625323.
source - https://xxxxxxxxxx.asco.org/record/188803/abstract
(replace xxxx with meeting library)
glta
- Forums
- ASX - By Stock
- IMM
- A major investor looks at the odds for IMM !
A major investor looks at the odds for IMM !, page-20
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
31.5¢ | 31.5¢ | 31.0¢ | $18.43K | 58.71K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
33 | 242291 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 84174 | 43 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
33 | 242291 | 0.310 |
26 | 405807 | 0.305 |
23 | 431489 | 0.300 |
10 | 114670 | 0.295 |
11 | 294184 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 100187 | 59 |
0.320 | 160299 | 13 |
0.325 | 248319 | 7 |
0.330 | 66808 | 6 |
0.335 | 335213 | 9 |
Last trade - 11.24am 07/10/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |